Anti-CD22 monoclonal antibody-toxin conjugate - Galileo Research/the University of Texas

Drug Profile

Anti-CD22 monoclonal antibody-toxin conjugate - Galileo Research/the University of Texas

Alternative Names: IMTOX 22 N97A; IMTOX-22; RFB4-N97A

Latest Information Update: 13 Feb 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Royal Free and University College Medical School; University of Texas Southwestern Medical Center
  • Developer Galileo Research; National Cancer Institute (USA)
  • Class Antineoplastics; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported B cell lymphoma

Most Recent Events

  • 13 Feb 2014 No development reported - Phase-I for B-cell lymphoma in USA (Parenteral)
  • 24 Nov 2010 Phase-I development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top